Botulinum toxin A - Galderma

Drug Profile

Botulinum toxin A - Galderma

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Galderma
  • Class Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Muscle relaxants
  • Mechanism of Action Acetylcholine inhibitors; Glutamate-antagonists; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Glabellar lines

Most Recent Events

  • 04 Apr 2017 No recent reports of development identified - Phase-II for Glabellar lines in USA (Parenteral)
  • 15 Mar 2016 Biomarkers information updated
  • 06 Oct 2014 Phase-II clinical trials in Glabellar lines in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top